OLMA
Olema Pharmaceuticals, Inc.
$13.68
-0.38
(-2.70%)
Mkt Cap
1.19B
Volume
1,038,480
52W Range
3.89-36.259
Sector
Healthcare
Beta
2.06
EPS (TTM)
-2.02
P/E Ratio
-13.39
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.45M) | (129.47M) | (96.66M) | (104.79M) | (71.10M) | (22.12M) | (4.32M) | (2.20M) |
| EPS | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 | -0.11 | -0.16 |
| Free Cash Flow | (146.72M) | (104.51M) | (83.73M) | (82.43M) | (52.27M) | (19.92M) | (3.08M) | (2.18M) |
| FCF / Share | -1.69 | -1.78 | -1.85 | -2.06 | -1.32 | -0.51 | -0.08 | -0.15 |
| Operating CF | (146.72M) | (104.35M) | (83.73M) | (82.06M) | (50.69M) | (19.87M) | (3.08M) | (2.18M) |
| Total Assets | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M | 342.72M | 132,000 | 3.27M |
| Total Debt | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M | 0 | 0 | 0 |
| Cash & Equiv | 48.30M | 139.48M | 68.54M | 23.70M | 13.81M | 338.55M | 68,000 | 3.15M |
| Book Value | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M | 338.14M | (10.59M) | (6.28M) |
| Return on Equity | -0.34 | -0.32 | -0.38 | -0.53 | -0.25 | -0.07 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (53.09M) | (46.06M) | (42.22M) | (43.78M) | (30.39M) | (33.57M) | (34.55M) | (30.38M) | (30.97M) | (26.77M) | (21.50M) | (20.09M) |
| EPS | -0.52 | -0.50 | -0.49 | -0.51 | -0.36 | -0.57 | -0.60 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 |
| Free Cash Flow | (45.99M) | (38.33M) | (34.53M) | (29.88M) | (43.98M) | (26.28M) | (27.02M) | (27.56M) | (23.65M) | (18.48M) | (22.74M) | (22.12M) |
| FCF / Share | -0.45 | -0.42 | -0.40 | -0.35 | -0.51 | -0.45 | -0.47 | -0.49 | -0.43 | -0.34 | -0.51 | -0.54 |
| Operating CF | (45.99M) | (38.33M) | (34.53M) | (29.88M) | (43.98M) | (26.28M) | (27.02M) | (27.55M) | (23.50M) | (18.48M) | (22.74M) | (22.12M) |
| Total Assets | 530.64M | 533.43M | 352.45M | 382.00M | 409.64M | 450.98M | 230.17M | 254.56M | 263.69M | 276.94M | 292.80M | 177.62M |
| Total Debt | 956,000 | 1.19M | 4.48M | 4.75M | 1.15M | 1.43M | 1.70M | 1.96M | 2.21M | 2.42M | 2.62M | 2.01M |
| Cash & Equiv | 52.55M | 48.30M | 35.26M | 52.47M | 50.64M | 139.48M | 35.89M | 16.89M | 33.72M | 68.54M | 117.41M | 34.96M |
| Book Value | 480.48M | 478.56M | 307.49M | 345.24M | 383.45M | 408.96M | 198.91M | 227.16M | 236.32M | 253.90M | 275.13M | 161.58M |
| Return on Equity | -0.11 | -0.10 | -0.14 | -0.13 | -0.08 | -0.08 | -0.17 | -0.13 | -0.13 | -0.11 | -0.08 | -0.12 |
OLMA News
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner